MyoPax
PrivateLast Round
Pre Seed
Nov 4, 2026
Total Funding Raised
$7.61M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
MyoPax operates in Healthcare & Life Sciences and is based in Berlin. Its latest recorded funding round was a Pre Seed round in November 2026.
MyoPax is a biotechnology company developing regenerative stem cell therapies for muscle diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MyoPax Comparables
Compare MyoPax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Myogenica, Inc. | 83% | |
| Atamyo Therapeutics | 82% | |
| Myostellar Pty Ltd | 80% |
For institutional investors. Book with your work email.
MyoPax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Nov 4, 2026 | ||||
| Grant | Feb 20, 2025 | ||||
| Convertible Debt | Sep 5, 2022 |
For institutional investors. Book with your work email.
MyoPax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| BioInnovation Institute | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 4, 2026
Completed a Pre Seed funding round.
- Feb 20, 2025
$3M grant received from European Innovation Council Fund.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 8, 2026
MyoPax GmbH is developing potential treatments for genetic muscle-wasting diseases using gene repair and muscle stem cell therapies to address disease-causing defects and support muscle tissue repair in Germany.
- is_developingNov 4, 2026
On Nov 4th '26 in Germany, MyoPax GmbH develops a therapeutic platform combining regenerative muscle stem cell therapy with CRISPR/Cas gene editing to repair congenital and acquired muscle defects and halt incurable muscle-wasting diseases.
For institutional investors. Book with your work email.
MyoPax Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MyoPax's valuation, stock price, and market status.
Is MyoPax a public or private company?
MyoPax is a private company.
What is the current stock price of MyoPax?
MyoPax is a private company, so its shares have no public market price. Caplight tracks MyoPax's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MyoPax worth (valuation)?
Valuation information for MyoPax is not publicly available.
Can I buy MyoPax stock?
MyoPax shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MyoPax's last funding round?
MyoPax's most recent funding round was Pre Seed on November 4, 2026.
Who are the main investors in MyoPax?
Key investors in MyoPax include BioInnovation Institute.
Will MyoPax IPO soon?
No public IPO plans have been announced for MyoPax.
How can I track MyoPax secondary market activity?
Caplight tracks bids, offers, and trades in MyoPax's shares on secondary markets.